Can risk factors and risk scores help predict colonization and infection in multidrug-resistant gram-negative bacteria?
- PMID: 39563931
- PMCID: PMC11574599
- DOI: 10.1017/ash.2024.455
Can risk factors and risk scores help predict colonization and infection in multidrug-resistant gram-negative bacteria?
Abstract
Antimicrobial resistance (AMR) is positioning as one of the most relevant threats to global public health and threatens the effective treatment of an ever-growing number of bacterial infections in various healthcare settings, particularly in acute care and surgical units, as well as in the community. Among multidrug-resistant (MDR) gram-negative bacteria (MDRGNB), Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii require special attention, since they account for most of the mortality associated with bacterial infections and are often MDR. It is clear that there is an important global variation in antibiotic resistance profiles among MDRGNB species. Extended-spectrum β-lactamase-producing Enterobacterales, carbapenem-resistant Enterobacterales, DTR-P. aeruginosa, and MDR-A. baumannii are the focus of this review. Here, we summarize a series of relevant studies on risk factors associated with colonization and infection with these MDRGNB. Likewise, we offer a comparative overview of those studies providing scoring systems to predict the risk of infection with these MDR pathogens, and their pros and cons. Despite the variable accuracy of published risk factors for predicting colonization or infection with MDRGNB, these scores are valuable tools that may help anticipate colonization and infection among those colonized. More importantly, they may help reduce unnecessary use of broad-spectrum antimicrobials and guiding the selection of an optimal treatment.
© The Author(s) 2024.
Conflict of interest statement
The authors declare the following financial interests/personal relationships that may be considered as potential competing interests. M.V.V. and C.J.P have received honoraria and research grants from MSD, Pfizer, bioMérieux, West and GPC pharma. S.S.K has received honoraria for participating in advisory boards and as a speaker from MSD, Pfizer, GSK, and Menarini. P.K has received honoraria for participating in an advisory board from Pfizer and as a speaker from bioMérieux, MSD and Pfizer. The other authors declare no competing financial interest. All authors, except J.C.G.B, C.J.P, N.R.A, and L.W.A received an honorarium from Pfizer to attend a steering committee meeting to discuss their regional perspective on MDR gram-negative infections and AMS strategies. The output of these discussions was used to create to a framework for this manuscript prior to its development.
References
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous